The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus
Open accessAbstract
BACKGROUND: We compared two strategies for treating patients infected with multidrug-resistant human immunodeficiency virus (HIV). METHODS: Patients with multidrug-resistant HIV and HIV RNA levels of more than 5000 copies per milliliter were randomly assigned to a four-month structured interruption of treatment followed by a change in antiretroviral regimen (treatment-interruption group) or to an immediate change in regimen (control group). Genotypic and phenotypic resistance testing was performed. Disease progression, death, and changes in genotypic resistance, CD4 cell counts, HIV RNA levels, and quality of life were assessed. RESULTS: After a median follow-up of 11.6 months, disease progression or death occurred in 22 of the 138 patients in the treatment-interruption group and in 12 of the 132 patients in the control group (P=0.01), with a hazard ratio of 2.57 (95 percent confidence interval, 1.2 to 5.5) for the treatment-interruption group. There were eight deaths in each group. In the treatment-interruption group, the mutant HIV populations completely or partially reverted to wild type by four months in 64.0 percent of patients. As compared with the control group, the treatment-interruption group had a mean CD4 cell count that was 85 cells per cubic millimeter lower from months 0 through 4 (P<0.001), 47 cells per cubic millimeter lower from months 5 through 8 (P<0.001), and 31 cells per cubic millimeter lower after eight months (P=0.11). The mean HIV RNA levels were 1.2 log copies per milliliter higher (on a base-10 scale) in the treatment-interruption group during months 0 through 4 (P<0.001), but they were not significantly different from those in the control group after month 4. The overall quality of life was similar in the two groups. CONCLUSIONS: In patients infected with multidrug-resistant HIV, structured interruption of treatment was associated with greater progression of disease and did not confer immunologic or virologic benefits or improve the overall quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deeks, S. G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J. D., Hellmann, N. S., Petropoulos, C. J., McCune, J. M., Hellerstein, M. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440702 · Cited by 653
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
Cohen, C. J., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S., Nadler, J., Verbiest, W., Hertogs, K., Ames, M., et al. (2002) · AIDS · doi:10.1097/00002030-200203080-00009 · Cited by 195
Deeks, S. G., Grant, R. M., Wrin, T., Paxinos, E. E., Liegler, T. J., Hoh, R., Martin, J. N., & Petropoulos, C. J. (2003) · AIDS · doi:10.1097/00002030-200302140-00010 · Cited by 89
Delaugerre, C., Valantin, M., Mouroux, M., Bonmarchand, M., Carcelain, G., Duvivier, C., Tubiana, R., Simon, A., Bricaire, F., Agut, H., et al. (2001) · AIDS · doi:10.1097/00002030-200111090-00016 · Cited by 59
Cited by
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 654
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Palmer, S., Kearney, M., Maldarelli, F., Halvas, E. K., Bixby, C. J., Bazmi, H., Rock, D., Falloon, J., Davey, R. T., Dewar, R. L., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.1.406-413.2005 · Cited by 506
Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies
Catalano, A., Iacopetta, D., Ceramella, J., Scumaci, D., Giuzio, F., Saturnino, C., Aquaro, S., Rosano, C., & Sinicropi, M. S. (2022) · Molecules · doi:10.3390/molecules27030616 · Cited by 450
Springer, S. A., Pesanti, E., Hodges, J., Macura, T., Doros, G., & Altice, F. L. (2004) · Clinical Infectious Diseases · doi:10.1086/421392 · Cited by 260
Metadata
- Authors
- Lawrence, J., Mayers, D. L., Hullsiek, K. H., Collins, G., Abrams, D. I., Reisler, R. B., Crane, L. R., Schmetter, B. S., Dionne, T. J., Saldanha, J. M., Jones, M. C., & Baxter, J. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-28
- Volume
- 349
- Issue
- 9
- Pages
- 837-846
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2051939247
- Cited by
- 268
- References
- 5
- FWCI
- 22.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus. https://app.cochat.ai/papers/10.1056/nejmoa035103
- The paper
- Lawrence, J., Mayers, D. L., Hullsiek, K. H., Collins, G., Abrams, D. I., Reisler, R. B., Crane, L. R., Schmetter, B. S., Dionne, T. J., Saldanha, J. M., Jones, M. C., & Baxter, J. D. (2003). Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus. New England Journal of Medicine. https://doi.org/10.1056/nejmoa035103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
